Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1358863X21995896 http://scihub22266oqcxt.onion/10.1177/1358863X21995896 33818200!8047511!33818200     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Vasc+Med 2021 ; 26 (4): 426-433 Nephropedia Template TP {{tp|p=33818200|t=2021. Pulmonary Embolism Response Team utilization during the COVID-19 pandemic |pdf=|usr=}}{{33818200}} gab.com Text Pulmonary Embolism Response Team utilization during the COVID-19 pandemic JO: Vasc Med http://www.kidney.de/pget.php?&tw=1&pmid=33818200 #FOAvip Coronavirus disease 2019 (COVID-19) may predispose patients to venous thromboembolism (VTE). Limited data are available on the utilization of the Pulmonary Embolism Response Team (PERT) in the setting of the COVID-19 global pandemic. We performed a single-center study to evaluate treatment, mortality, and bleeding outcomes in patients who received PERT consultations in March and April 2020, compared to historical controls from the same period in 2019. Clinical data were abstracted from the electronic medical record. The primary study endpoints were inpatient mortality and GUSTO moderate-to-severe bleeding. The frequency of PERT utilization was nearly threefold higher during March and April 2020 (n = 74) compared to the same period in 2019 (n = 26). During the COVID-19 pandemic, there was significantly less PERT-guided invasive treatment (5.5% vs 23.1%, p = 0.02) with a numerical but not statistically significant trend toward an increase in the use of systemic fibrinolytic therapy (13.5% vs 3.9%, p = 0.3). There were nonsignificant trends toward higher in-hospital mortality or moderate-to-severe bleeding in patients receiving PERT consultations during the COVID-19 period compared to historical controls (mortality 14.9% vs 3.9%, p = 0.18 and moderate-to-severe bleeding 35.1% vs 19.2%, p = 0.13). In conclusion, PERT utilization was nearly threefold higher during the COVID-19 pandemic than during the historical control period. Among patients evaluated by PERT, in-hospital mortality or moderate-to-severe bleeding were not significantly different, despite being numerically higher, while invasive therapy was utilized less frequently during the COVID-19 pandemic. Twit Text FOAVip Pulmonary Embolism Response Team utilization during the COVID-19 pandemic ????Vasc Med http://www.kidney.de/pget.php?&tw=1&pmid=33818200 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33818200 #FOAvip English Wikipedia <ref>{{Cite pmid|33818200}}</ref> Pulmonary Embolism Response Team utilization during the COVID-19 pandemic #MMPMID33818200 Finn MT; Gogia S; Ingrassia JJ; Cohen M; Madhavan MV; Nabavi Nouri S; Brailovsky Y; Masoumi A; Fried JA; Uriel N; Agerstrand CI; Eisenberger A; Einstein AJ; Brodie D; B Rosenzweig E; Leon MB; Takeda K; Pucillo A; Green P; Kirtane AJ; Parikh SA; Sethi SS Vasc Med 2021[Aug]; 26 (4): 426-433 PMID33818200show ga Coronavirus disease 2019 (COVID-19) may predispose patients to venous thromboembolism (VTE). Limited data are available on the utilization of the Pulmonary Embolism Response Team (PERT) in the setting of the COVID-19 global pandemic. We performed a single-center study to evaluate treatment, mortality, and bleeding outcomes in patients who received PERT consultations in March and April 2020, compared to historical controls from the same period in 2019. Clinical data were abstracted from the electronic medical record. The primary study endpoints were inpatient mortality and GUSTO moderate-to-severe bleeding. The frequency of PERT utilization was nearly threefold higher during March and April 2020 (n = 74) compared to the same period in 2019 (n = 26). During the COVID-19 pandemic, there was significantly less PERT-guided invasive treatment (5.5% vs 23.1%, p = 0.02) with a numerical but not statistically significant trend toward an increase in the use of systemic fibrinolytic therapy (13.5% vs 3.9%, p = 0.3). There were nonsignificant trends toward higher in-hospital mortality or moderate-to-severe bleeding in patients receiving PERT consultations during the COVID-19 period compared to historical controls (mortality 14.9% vs 3.9%, p = 0.18 and moderate-to-severe bleeding 35.1% vs 19.2%, p = 0.13). In conclusion, PERT utilization was nearly threefold higher during the COVID-19 pandemic than during the historical control period. Among patients evaluated by PERT, in-hospital mortality or moderate-to-severe bleeding were not significantly different, despite being numerically higher, while invasive therapy was utilized less frequently during the COVID-19 pandemic. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19/complications/diagnosis/mortality/*therapy[MESH] |Female[MESH] |Health Resources/*trends[MESH] |Health Services Needs and Demand/*trends[MESH] |Hemorrhage/etiology/mortality[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Patient Care Team/*trends[MESH] |Practice Patterns, Physicians'/*trends[MESH] |Pulmonary Embolism/diagnosis/etiology/mortality/*therapy[MESH] |Retrospective Studies[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |Thrombolytic Therapy/*trends[MESH] |Time Factors[MESH] |Treatment Outcome[MESH]Pulmonary Embolism Response Team utilization during the COVID-19 pande(epmc).pdf DeepDyve Pubget Overpricing